Phase IV CAPTOR-BC Study to Assess Ribociclib's Efficacy and Resistance in Advanced Breast Cancer
New Study Aims to Evaluate Treatment Options for patients with advanced HER2-negative Breast Cancer
Study Parameters and Objectives
CAPTOR-BC (NCT054552213) is a single-arm, open-label Phase IV clinical trial designed to assess the efficacy and resistance patterns of Ribociclib in patients with advanced Human epidermal growth factor receptor 2 (HER2)-negative, hormone receptor-positive (HR-positive) breast cancer.
The study primarily aims to evaluate the efficacy of Ribociclib as a monotherapy for patients who have progressed on or after prior endocrine therapy and at least one line of chemotherapy in the advanced setting.
Comments